Proposed Changes to the Medicare Part B Drug Benefit

Proposed Changes to the Medicare Part B Drug Benefit

The Center for Medicare and Medicaid Services (CMS) recently proposed changes to Medicare Part B that would significantly alter the program’s reimbursement structure, essentially importing price controls from other countries with government-controlled healthcare systems.  There are concerns that this could affect patient access to care – drugs administered in the Part B program are vital to many patients with serious, life-threatening illnesses – and the ability to develop new cures and treatments.  To assist with education and advocacy efforts, a list of resources from patient, provider, and consumer groups, as well as media commentary, can be found below.

Part B Proposal Overview

Healthcare Leadership Council Press Statement

HealthExec Article: Not everyone agrees Trump’s new drug pricing model will work

Forbes Opinion Piece: Trump’s Proposed Medicare Drug Pricing Experiment Stokes Fears Of Price Controls

National Hispanic Council on Aging Press Statement

National Minority Quality Forum Press Statement

US Oncology Network Press Statement

Council for Affordable Health Coverage Press Statement

Association of Community Cancer Centers Press Statement

Citizens Against Government Waste Press Statement

Cato Institute Press Statement

Americans for Tax Reform Press Statement

Wall Street Journal Editorial